AR124720A1 - Derivados de pirazolamida - Google Patents
Derivados de pirazolamidaInfo
- Publication number
- AR124720A1 AR124720A1 ARP220100176A ARP220100176A AR124720A1 AR 124720 A1 AR124720 A1 AR 124720A1 AR P220100176 A ARP220100176 A AR P220100176A AR P220100176 A ARP220100176 A AR P220100176A AR 124720 A1 AR124720 A1 AR 124720A1
- Authority
- AR
- Argentina
- Prior art keywords
- pyrazolamide
- derivatives
- formula
- present
- compounds
- Prior art date
Links
- BNYCHCAYYYRJSH-UHFFFAOYSA-N 1h-pyrazole-5-carboxamide Chemical class NC(=O)C1=CC=NN1 BNYCHCAYYYRJSH-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
La presente invención proporciona compuestos de fórmula (1) en donde X¹, R¹ y R² son como se describe en la presente, así como también sales de estos aceptables desde el punto de vista farmacéutico. Además, la presente invención se refiere a la fabricación de compuestos de fórmula (1), composiciones farmacéuticas que los comprenden y su uso como medicamentos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21154295 | 2021-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124720A1 true AR124720A1 (es) | 2023-04-26 |
Family
ID=74418268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100176A AR124720A1 (es) | 2021-01-29 | 2022-01-28 | Derivados de pirazolamida |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230382911A1 (es) |
| EP (1) | EP4284797A1 (es) |
| JP (1) | JP2024504788A (es) |
| KR (1) | KR20230141787A (es) |
| CN (1) | CN116867782A (es) |
| AR (1) | AR124720A1 (es) |
| AU (1) | AU2022212487A1 (es) |
| CA (1) | CA3209599A1 (es) |
| CL (1) | CL2023002052A1 (es) |
| CO (1) | CO2023010155A2 (es) |
| CR (1) | CR20230331A (es) |
| IL (1) | IL304189A (es) |
| MX (1) | MX2023008562A (es) |
| PE (1) | PE20231387A1 (es) |
| TW (1) | TW202246259A (es) |
| WO (1) | WO2022162034A1 (es) |
| ZA (1) | ZA202306694B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024151112A1 (ko) * | 2023-01-11 | 2024-07-18 | 주식회사 티움바이오 | 사이클린 의존성 키나아제 9 저해제로서의 피라졸로피리미딘 유도체 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014207213A1 (en) * | 2013-06-28 | 2014-12-31 | Medizinische Universität Innsbruck | Novel inhibitors of protein kinase c epsilon signaling |
| JP6806342B2 (ja) | 2015-04-10 | 2021-01-06 | ベイジーン リミテッド | インドールアミンとしての新規５又は８−置換イミダゾ［１，５−ａ］ピリジン類、及び／又はトリプトファン２，３−ジオキシゲナーゼ |
| CN106146493A (zh) | 2015-04-21 | 2016-11-23 | 中国科学院上海药物研究所 | 吡唑并[3,4-b]吡啶类和吲唑类化合物的制备方法和用途 |
-
2022
- 2022-01-26 TW TW111103282A patent/TW202246259A/zh unknown
- 2022-01-27 JP JP2023545924A patent/JP2024504788A/ja active Pending
- 2022-01-27 CA CA3209599A patent/CA3209599A1/en active Pending
- 2022-01-27 KR KR1020237026475A patent/KR20230141787A/ko unknown
- 2022-01-27 EP EP22702930.3A patent/EP4284797A1/en active Pending
- 2022-01-27 CR CR20230331A patent/CR20230331A/es unknown
- 2022-01-27 AU AU2022212487A patent/AU2022212487A1/en active Pending
- 2022-01-27 MX MX2023008562A patent/MX2023008562A/es unknown
- 2022-01-27 CN CN202280012462.8A patent/CN116867782A/zh active Pending
- 2022-01-27 WO PCT/EP2022/051823 patent/WO2022162034A1/en active Application Filing
- 2022-01-27 PE PE2023002122A patent/PE20231387A1/es unknown
- 2022-01-28 AR ARP220100176A patent/AR124720A1/es unknown
-
2023
- 2023-06-29 ZA ZA2023/06694A patent/ZA202306694B/en unknown
- 2023-07-02 IL IL304189A patent/IL304189A/en unknown
- 2023-07-14 CL CL2023002052A patent/CL2023002052A1/es unknown
- 2023-07-28 CO CONC2023/0010155A patent/CO2023010155A2/es unknown
- 2023-07-28 US US18/361,526 patent/US20230382911A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202306694B (en) | 2024-03-27 |
| AU2022212487A1 (en) | 2023-07-13 |
| MX2023008562A (es) | 2023-08-08 |
| IL304189A (en) | 2023-09-01 |
| CR20230331A (es) | 2023-09-01 |
| CO2023010155A2 (es) | 2023-09-08 |
| US20230382911A1 (en) | 2023-11-30 |
| WO2022162034A1 (en) | 2022-08-04 |
| CL2023002052A1 (es) | 2023-12-22 |
| PE20231387A1 (es) | 2023-09-12 |
| CN116867782A (zh) | 2023-10-10 |
| TW202246259A (zh) | 2022-12-01 |
| EP4284797A1 (en) | 2023-12-06 |
| CA3209599A1 (en) | 2022-08-04 |
| KR20230141787A (ko) | 2023-10-10 |
| JP2024504788A (ja) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023021383A2 (pt) | Composto da fórmula geral 1, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 2, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 3, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 4, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 5, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composição farmacêutica; e; uso do composto, ou do isômero, da forma cristalina, do sal farmaceuticamente aceitável, do hidrato ou do solvato do mesmo | |
| CO2023000056A2 (es) | Derivados de amidopirimidona | |
| UY29825A1 (es) | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones | |
| DOP2022000158A (es) | Agonistas heterocíclicos de glp-1 | |
| UY31254A1 (es) | Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones | |
| UY30804A1 (es) | Derivados de nicotinamida, sus sales y solvatos, composiciones farmacéuticas conteniendolas y aplicaciones | |
| UY33500A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| CL2022003045A1 (es) | Quimioterápicos de éter macrocíclico heteroaromático solicitudes relacionadas | |
| UY35535A (es) | ?Derivados de fenil sulfonamidas?. | |
| CL2020001817A1 (es) | Moduladores del receptor c5a | |
| CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
| CL2021002621A1 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| MX2020003993A (es) | Derivados de bencimidazol y sus usos. | |
| PH12020551341A1 (en) | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof | |
| CL2023003223A1 (es) | Derivado de fosfonilo, y composición y aplicación farmacéutica de este | |
| UY39181A (es) | COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO | |
| AR124720A1 (es) | Derivados de pirazolamida | |
| UY38488A (es) | Derivados de pirazol y su uso en medicina | |
| ECSP23070418A (es) | Moduladores de sting (estimulador de genes de interferón) | |
| CO2023000117A2 (es) | Derivados de sulfona | |
| AR125059A1 (es) | Degradadores selectivos del receptor de estrógeno | |
| ECSP23075535A (es) | Compuestos cíclicos y métodos de uso | |
| CL2023002322A1 (es) | Derivados de hidroxiheterocicloalquil-carbamoilo | |
| CL2023000970A1 (es) | Espiro derivados de alfa-d-galactopiranosidos | |
| AR049638A1 (es) | Derivados de benzileter, su elaboracion, su uso para preparar agentes farmaceuticos y composicion farmaceutica |